Multiple myeloma care, treatment patterns, and treatment durations in academic and community care settings.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-21 DOI:10.1080/14796694.2025.2504318

Natalie Boytsov, Catherine B McGuiness, Zifan Zhou, Tianyao Huo, Kathleen Montgomery, Nirali Kotowsky, Chi-Chang Chen

{"title":"Multiple myeloma care, treatment patterns, and treatment durations in academic and community care settings.","authors":"Natalie Boytsov, Catherine B McGuiness, Zifan Zhou, Tianyao Huo, Kathleen Montgomery, Nirali Kotowsky, Chi-Chang Chen","doi":"10.1080/14796694.2025.2504318","DOIUrl":null,"url":null,"abstract":"Aim: Evaluate multiple myeloma (MM) treatment patterns, healthcare utilization (HCRU), and costs from academic and community settings.Methods: This observational study linked US MM insurance claims (1 April 2017-30 June 2022) with provider affiliations to evaluate patient characteristics and treatment durations across patient cohorts defined by care setting of treatment (academic only, community only, mixed [both]), as well as treatment patterns, HCRU, and costs of care (e.g. treatment, office visits, hospitalization) in each setting.Results: 3778 patients were included. By cohort (n = 530 academic; n = 1647 community), the community cohort was older with more comorbidities. Mixed-cohort patients (n = 1601) frequently initiated treatment at community centers and briefly shifted to academic centers for transplant. Among 3778 patients who received MM-related care, most claims were from the community setting. The academic setting had high rates of claims for proteasome inhibitors (56.3% of patients) and steroids (52.5%); the community setting had high rates for immunomodulatory drugs (75.1%) and steroids (85.0%). Stem cell transplant claims were more common for academic versus community (21.4%/7.3%). Treatment duration/time to next therapy were similar between cohorts. Costs were generally higher in the academic versus community settings.Conclusion: Improved patient support is needed in community settings, where most MM care occurs.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1905-1918"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150631/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2504318","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Evaluate multiple myeloma (MM) treatment patterns, healthcare utilization (HCRU), and costs from academic and community settings.

Methods: This observational study linked US MM insurance claims (1 April 2017-30 June 2022) with provider affiliations to evaluate patient characteristics and treatment durations across patient cohorts defined by care setting of treatment (academic only, community only, mixed [both]), as well as treatment patterns, HCRU, and costs of care (e.g. treatment, office visits, hospitalization) in each setting.

Results: 3778 patients were included. By cohort (n = 530 academic; n = 1647 community), the community cohort was older with more comorbidities. Mixed-cohort patients (n = 1601) frequently initiated treatment at community centers and briefly shifted to academic centers for transplant. Among 3778 patients who received MM-related care, most claims were from the community setting. The academic setting had high rates of claims for proteasome inhibitors (56.3% of patients) and steroids (52.5%); the community setting had high rates for immunomodulatory drugs (75.1%) and steroids (85.0%). Stem cell transplant claims were more common for academic versus community (21.4%/7.3%). Treatment duration/time to next therapy were similar between cohorts. Costs were generally higher in the academic versus community settings.

Conclusion: Improved patient support is needed in community settings, where most MM care occurs.

查看原文本刊更多论文

多发性骨髓瘤的护理，治疗模式，和治疗持续时间在学术和社区护理设置。

目的：评估多发性骨髓瘤（MM）的治疗模式、医疗保健利用率（HCRU）以及学术和社区环境的成本。方法：本观察性研究将美国MM保险索赔（2017年4月1日至2022年6月30日）与提供者关系联系起来，以评估由治疗护理环境（仅限学术，仅限社区，混合[两者]）定义的患者队列的患者特征和治疗持续时间，以及治疗模式，HCRU和护理成本（例如治疗，办公室就诊，住院）。结果：共纳入3778例患者。按队列(n = 530，学术；N = 1647个社区)，社区队列年龄较大，合并症较多。混合队列患者（n = 1601）经常在社区中心开始治疗，并短暂转移到学术中心进行移植。在3778名接受mm相关护理的患者中，大多数来自社区环境。学术环境对蛋白酶体抑制剂（56.3%的患者）和类固醇（52.5%）的要求率很高；社区使用免疫调节药物（75.1%）和类固醇（85.0%）的比例较高。干细胞移植的要求在学术界比社区更常见（21.4%/7.3%）。治疗持续时间/到下一次治疗的时间在队列之间相似。与社区环境相比，学术环境的成本通常更高。结论：在大多数MM护理发生的社区环境中，需要改善患者支持。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.